Biosimilars antibodies: positioning compared to originators-the experience in rheumatology and the biosimilars of trastuzumab in oncology

被引：0
|
作者：
Pivot, Xavier [1 ]
Goupille, Philippe [2 ,3 ]
机构：
[1] Inst Cancerol Strasbourg, Ctr Paul Strauss, Strasbourg, France
[2] Univ Tours, EA 7501, GICC, Tours, France
[3] CHRU Tours, Serv Rhumatol, Tours, France
来源：
M S-MEDECINE SCIENCES | 2020年 / 35卷 / 12期
关键词：
RANDOMIZED PHASE-I; BREAST-CANCER; DOUBLE-BLIND; PHARMACOKINETICS; SAFETY; INFLIXIMAB; SWITCH; IMMUNOGENICITY; BIOEQUIVALENCE; EQUIVALENCE;
D O I：
10.1051/medsci/2019214
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Biosimilars have demonstrated their equivalence with biologic originators, according to rigorous specifications imposed by the regulatory agencies, the FDA and the EMA. Their development is justified by the very high cost of biopharmaceuticals, and strong incentives for their prescription lead us to hope substantial savings, allowing to finance other innovative molecules. Trastuzumab marked history of the treatment of breast cancer. Four biosimilars of trastuzumab are available for routine use and we will detail the key points of their development.
引用
收藏
页码：1137 / 1145
页数：9
相关论文
共 33 条
  • [21] Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group
    Demirkan, Fatma Gul
    Ulu, Kadir
    Ozturk, Kubra
    Karadas, Serife Gul
    Ozdel, Semanur
    Sonmez, Hafize Emine
    Cakmak, Figen
    Demir, Ferhat
    Sozeri, Betul
    Ayaz, Nuray Aktay
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (02) : 197 - 202
  • [22] BIOSIMILARS IN RHEUMATOLOGY CLINICAL PRACTICEGAINING ACCEPTANCE IN DEVELOPING WORLD-EXPERIENCE FROM SOUTH INDIA
    Nallasivan, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1032 - 1032
  • [23] PERSISTENCE ON TREATMENT AND SAFETY OF TNF-ALPHA INHIBITORS BIOSIMILARS COMPARED TO ORIGINATORS: AN OBSERVATIONAL STUDY ON THE FRENCH NATIONAL HEALTH DATA SYSTEM
    Jourdain, H.
    Hoisnard, L.
    Sbidian, E.
    Zureik, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 793 - 793
  • [24] RELATIONSHIP BETWEEN THE DURATION OF RHEUMATOLOGY PRACTICE EXPERIENCE AND LIKELIHOOD OF USE AND PERCEPTION TOWARDS BIOSIMILARS IN RHEUMATOID ARTHRITIS ARENA
    Narayanan, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 624 - 624
  • [25] Clinical and treatment characteristics of patients treated with the first therapeutic oncology biosimilars bevacizumab-awwb and trastuzumab-anns in the US
    Jin, Ran
    Mahtani, Reshma L.
    Accortt, Neil
    Lawrence, Tatiana
    Sandschafer, Darcie
    Loaiza-Bonilla, Arturo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [26] Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars
    Azuz, Samuel
    Newton, Max
    Bartels, Dorthe
    Poulsen, Birgitte Klindt
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (10) : 1495 - 1501
  • [27] Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars
    Samuel Azuz
    Max Newton
    Dorthe Bartels
    Birgitte Klindt Poulsen
    European Journal of Clinical Pharmacology, 2021, 77 : 1495 - 1501
  • [28] RELATIONSHIP BETWEEN THE DURATION OF RHEUMATOLOGY PRACTICE EXPERIENCE AND LIKELIHOOD OF USE AND PERCEPTION TOWARDS BIOSIMILARS IN RHEUMATOID ARTHRITIS (RA) ARENA
    Narayanan, S.
    VALUE IN HEALTH, 2014, 17 (03) : A55 - A55
  • [29] Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
    Piezzo, Michela
    D'Aniello, Roberta
    Avallone, Ilaria
    Barba, Bruno
    Cianniello, Daniela
    Cocco, Stefania
    D'Avino, Antonio
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Fusco, Giuseppina
    Piscitelli, Raffaele
    von Arx, Claudia
    De Laurentiis, Michelino
    Maiolino, Piera
    PHARMACEUTICS, 2021, 13 (05)
  • [30] MONOCLONAL ANTIBODIES BIOSIMILARS IN THE US: WHAT LESSONS CAN BE DRAWN FROM THE RECENT EUROPEAN, SOUTH KOREAN AND JAPANESE EXPERIENCE?
    Bocquet, F.
    Loubiere, A.
    Paubel, P.
    VALUE IN HEALTH, 2017, 20 (05) : A18 - A19
1234